05-30pm_0415_stevenferguson_techtransferhowtomakeiteasy
DESCRIPTION
Products, Partners & Public Health: C ilii N Commercializing New TechnologiesFromIntramuralNIH Technologies From IntramuralNIH Steven M. Ferguson DeputyDirector Licensing&Entrepreneurship Deputy Director, Licensing & Entrepreneurship NIH Office of Technology Transfer HHSEmail:sf8h@nihgo HHS Email: [email protected] In biomedical research research, we’d like to think that all roadswill roads will eventually l dt lead to Bethesda…TRANSCRIPT
Products, Partners & Public Health: C i li i NCommercializing New
Technologies From Intramural NIHTechnologies From Intramural NIH
Steven M. FergusonDeputy Director Licensing & EntrepreneurshipDeputy Director, Licensing & Entrepreneurship
NIH Office of Technology TransferHHS Email: sf8h@nih goHHS Email: [email protected]
In biomedical researchresearch, we’d like to think that all roads willroads will eventually l d tlead to Bethesda…
NIH – U S National MedicalNIH U.S. National Medical Research Agency
• Annual budget of $ 30.9 billion (FY12) • 10% of funding for intramural research• 6,000 intramural scientists / 18,000 staff / 2,000 projects, , , p j• 325,000 extramural scientists /50,000 grants / 3,000
organizationsorganizations• Basic & clinical research discoveries
P i li i d• Partners commercialize into products
The National Institutes of Health
NLM
27 Institutes and CentersCC CIT
CSRNLM
FICNCCAM
NINRNINDS
NIMH
CIT
NCMHD
NIGMS
NCCAM
NCI
NIMH
NIEHS
NIDCR NEI
NIDDK NCRR
NIDCD NHGRI
NHLBINIA
NIDANICHD
NIBIBNIA
NIAIDNIAMSNIAAA
NICHD
National Institutes of HealthSupport of Biomedical Research pp f
to Benefit Public Health
• Funding• Training
• Clinical Trials• Inventions• Training
• Basic Research• Inventions• Policies
Why NIH Intramural Research ProgramsWhy NIH Intramural Research Programs Are Attractive For Commercial Licensors
• Novel, fundamental research discoveries• “Supermarket” for research tools • Collaborations generally available for basic or g y
clinical (applied) studies• Selected projects in early clinical developmentSelected projects in early clinical development• Licensees do $6B in annual sales
Goals For Intramural NIH TechnologyGoals For Intramural NIH Technology Transfer Programs
• Benefit the public health
• Utilize IP appropriately as incentive for commercial development of technologiesp g
• Attract new R&D resources
• Obtain public return on public investment
• Stim late economic de elopment• Stimulate economic development
Future Commercial ProductsFuture Commercial Products Licensable From Several Sources
• Intramural Research (from the NIH Office of Technology Transfer)
• University Grantee Research (from specific y ( puniversity technology transfer offices)
• SBIR and STTR Programs (from smallSBIR and STTR Programs (from small business awardees)
• New SBIR TT Program (combines SBIR award• New SBIR –TT Program (combines SBIR award & intramural license agreement)
Intramural NIH Basic & Clinical Research Collaborations
Intramural NIH ResearchIntramural NIH Research Collaboration Mechanisms
• Material Transfer Agreement (MTA) - non-profit• Cooperative Research And DevelopmentCooperative Research And Development
Agreement (CRADA) - for-profit• Clinical Trial Agreement• Clinical Trial Agreement• Specialized Development Services• Training Programs• Informal “official duty” collaborationsy
CRADA - Cooperative Research andCRADA Cooperative Research and Development Agreement
• Collaboration between Government lab & outside party
• Government provides expertise, equipment & materials
C ll b id d ibl• Collaborator provides same and possibly money
• Provides Collaborator with right to elect exclusiveProvides Collaborator with right to elect exclusive option to new inventions
Industry Interactions With NIHIndustry Interactions With NIH Intramural Scientists
• Collaborations should be “official duty” projects• Informal -- uncompensatedp
• Formal (CRADAs, CTAs) -- uncompensated
Fi i l f i i i i l• Financial support from company is to institution only • Public-Private-Partnerships via FNIH
• Lab funding (under CRADA)
• Royalty income under licenses (shared with inventors)• Royalty income under licenses (shared with inventors)
Technology Licensing At NIHTechnology Licensing At NIH
NIH Product Licensing Principles
• Granting only the appropriate scope of rights• Permit research usesPermit research uses• Preference for non or partial exclusivity
S ifi d fi ld f• Specified fields of use • Enforceable benchmarks
Typical Types Of Royalties In NIHTypical Types Of Royalties In NIH Intramural Licenses
• Execution RoyaltyMi i A l R lt ( dl f th• Minimum Annual Royalty (regardless of the amount of Net Sales
• Earned Royalties (fixed % of Net Sales)• Benchmark Royaltiesy• Patent Costs• Equity (?)• Equity (?)
Typical Factors Influencing Royalty Rate NegotiationsRate Negotiations
St f D l t S f P t t• Stage of Development• Type of Product
• Scope of Patent Coverage
• Market Value of Product
• Market Timing• “Content” in Final
• Uniqueness of Materials
Product• Public HealthMaterials Public Health
Research Products Licensed From NIH
i l h d iTypical Research Products License (Commercialization)(Commercialization)
• Non-exclusiveNon exclusive• Materials provided (patented or unpatented)
S ll fi d i t li• Smaller firms predominate as licensees• High earned royalty rates• Low upfront costs• Products: CHAPS, antisera, mabsProducts: CHAPS, antisera, mabs
i l h d iTypical Research Products License (Internal Use)(Internal Use)
• Non-exclusive• Non-exclusive• Materials provided / screening use permitted
h h h d• No reach through to products• Larger firms predominant• Paid-up term licenses or annual fees• Products: muscarinic receptorsProducts: muscarinic receptors
Diagnostic & Therapeutic Products Licensed From NIHLicensed From NIH
i l i i i OTypical Vaccine, Diagnostic Or Therapeutic LicenseTherapeutic License
• Exclusive if required for developmentExclusive if required for development• Most major pharma or biotech have at least one
D t il d d l t l ith b h k• Detailed development plan with benchmarks• Preference for capable small firms• CRADA research separate from license• U.S. manufacturing for U.S. product salesU.S. manufacturing for U.S. product sales
T i l V i Di ti OTypical Vaccine, Diagnostic Or Therapeutic License (Cont.)p ( )
• Substantial upfront feesp• Moderate earned royalties• Appropriate benchmark payments• Appropriate benchmark payments• Share sublicensing payments• “White Knight” (public benefit) provisions• Monitor performance of licenseep
Old “ ” i dOlder NIH “Homerun” Licensed ProductsProducts
• Abbott HIVAB (AIDS Test Kit)( )• BMS Videx (ddI)• BMS Taxol (paclitaxel)• BMS Taxol (paclitaxel)• Schering Fludara (fludarabine)• GlaxoSKB Havrix (hepatitis A)• Roche Hivid (ddC)( )
M R t P d t A lMore Recent Product Approvals
• Angiotech Taxus (paclitaxel-eluting stents)• Genzyme Thyrogen (rTSH)• Isis Vitravene (antisense CMV)• Medimmune Synagis (RSV mab)• Millennium Velcade (myeloma drug)• Millennium Velcade (myeloma drug)• Biogen Idec Zevalin (NHL I131 mab)
i ( )• Amgen Kepivance (KGF)
AcuTect AIDS Test Kit Beaucage Reagent BRCA1 Diagnostic CertivaReagent BRCA1 Diagnostic Certiva
CHAPS Fludara Fecolator HavrixImmunoWELL® Matrigel®ImmunoWELL® Matrigel®
Invasion Chamber MirakelleNeuTrexin® ParaSightF PixCell
Soluble Interleukin-2 Receptor Squirrel Free Seed Saver Synagis Taxol®Thyrogen TransProbe-1® Videx®Thyrogen TransProbe 1® Videx®
Vitravene
NIH Licensing Portfolio
> 600 products developed to date (25 vaccines and therapeutics)( p )
Over 84% licenses – non-exclusive
Over 86% licenses – U.S. firms
O 52% li ll iOver 52% licenses – small companies
Annual Sales By Licensees – nearly $6By y
NIH Technology PortfolioNIH Technology Portfolio• 351 invention disclosures per year (FY11)• 351 invention disclosures per year (FY11)
• ~3500 total pending/issued patents p g p(131 U.S. Patents issued FY11)
1300+ ti li (197 t d FY11)• ~1300+ active licenses (197 executed FY11)
• $96.9 million in royalties collected FY11$ y
• 68 CRADAs executed FY11
Pilot Program In FY12:E St t Li A tExpress Start-up License Agreements
For Small Companiesp• Up to 50 employees, in business up to 5 years with
i d i l $raised capital up to $5M• For vaccine, drugs or other therapeutics• 1 year option agreement for $2K• Convertible to exclusive license with heavilyConvertible to exclusive license with heavily
deferred financial terms• Financial terms pre set• Financial terms pre-set
New In FY11: SBIR-Technology gyTransfer (TT) Contract Awards
• Pilot study from National Cancer Institute (NCI) and h Offi f h l f (O )the NIH Office of Technology Transfer (OTT)
• Out-licensing bundles with SBIR funding to move inventions from intramural NIH to the market
• Pilot is based on the successful program at NISTp g• In FY11, two SBIR-TT “Requests For Proposals”
(RFPs) were guaranteed funding & published• Program is being expanded to other NIH SBIR offices
C ll b ti SBIR TT C t tCollaborations on SBIR-TT Contracts
NIH labs can collaborate under many different formatsCompany can exchange knowledge with the NIH researcherp y g gCompany can utilize fixed asset resources at NIH
Company cannot contact NIH researchers prior to contract p y pawardCompany cannot rely on the NIH lab to perform the majority p y y p j yof the effort being proposed for the SBIR contractCompany cannot fund work in NIH lab using SBIR money under a CRADA
The SBIR- TT Internal Use LicenseThe SBIR TT Internal Use License
• “Royalty-free, non-exclusive” internal use license given with SBIR-TT award periodg p
• SBIR-TT research completed without infringement of NIH patentsof NIH patents
• Internal R & D allowed using the invention, but not sales of the final commercial productsales of the final commercial product
The SBIR-TT Commercialization License
• Need to develop NIH invention into a commercial product that benefits the public
• Commercialization license required to sell product (if issued IP claims) and/or requested (if only pending claims)
• Commercialization license also required for each SBIR-TT Phase II topic
• License terms are negotiable
• For internal use license agreements• Select materials for licensing from on-line catalog• Clickable license agreement (with terms) available • Payments made through www.pay.gov (like PayPal)y e s de oug www.p y.gov ( e y )• Faster means of getting materials for corporate R&D
How To Find Technologies• NIH/FDA Licensing Opportunities
– iPhone apppphttp://itunes.apple.com/us/app/nih-ott-licensing-opportunities/id401257307?mt=8#
– Searchable databasehttp://www.ott.nih.gov/search
– Technologies RSS Feedhttp://www.ott.nih.gov/rss
Neglected Diseases– Neglected Diseaseshttp://www.ott.nih.gov/nd
– Rare Diseaseshttp://www ott nih gov/rdhttp://www.ott.nih.gov/rd
– Federal Registerhttp://www.gpo.gov/fdsys/browse/collection.action?collectionCode=FR
• CRADA Opportunities RSS Feedhttp://www.ott.nih.gov/rss/cradarss.xml
NIH: Products Partners & PublicNIH: Products, Partners & Public Health since 1887
• NIH Information: www.nih.gov• Office of Technology Transfer: www.ott.nih.gov